Trial Date Set for Patent Infringement Suit Against Sepracor's Brovana(TM)
- Dey, L.P. suit alleges Sepracor infringes multiple patents with Brovana(TM) (arformoterol tartrate) Inhalation Solution for treatment of COPD -
NAPA, Calif., Sept. 21 /PRNewswire/ -- Dey, L.P. announced that the United States District Court of New York has issued a Scheduling Order setting December 12, 2008 as the trial date for the Company's intellectual property infringement suit against Sepracor for Brovana(TM) (arformoterol tartrate) Inhalation Solution. DEY's suit seeks redress against Sepracor for knowingly infringing multiple DEY patents through its marketing of Brovana(TM), a treatment for Chronic Obstructive Pulmonary Diseases (COPD).
About Dey, L.P.
Dey, L.P. is a specialty pharmaceutical company focused on the
development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies, and emergency care medicine. As the US leader in nebulized respiratory medication, DEY puts patients first through its development of innovative and affordable therapies. The Web sites for DEY include
dey.com,
accuneb.com, curosurfusa.com, cyanokit.com, duoneb.com,
epipen.com and perforomist.com.
Dey, L.P. is an affiliate of Merck KGaA, Darmstadt, Germany. |
